Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00382668 · ClinicalTrials.gov registry record
A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug
A clinical trial of Liver Diseases, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 40
- Enrollment target
- 4
- Study locations
NCT00382668: Completed study of Liver Diseases, sponsored by Bristol-Myers Squibb.
NCT00382668 is a study of Liver Diseases that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 40 participants, below the 61,157-participant average among 33 other Liver Diseases trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00382668, a study of Liver Diseases, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary purpose of this study is to evaluate how a person with liver impairment processes and reacts to the study drug. Information about any side effects that may occur will also be collected.
Conditions Studied
Interventions
- DRUG Dasatinib
Study Locations (4)
Florida
- University Of Miami - Miami
- Comprehensive Phase One - Miramar
- Orlando Clinical Research Center - Orlando
Tennessee
- New Orleans Center For Clinical Research - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-08 |
What the finished NCT00382668 record still lists
NCT00382668 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 61,157-participant average among 33 other Liver Diseases trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Liver Diseases appearing as the primary indexed condition, and to 1 intervention - of which Dasatinib is the first listed.
NCT00382668 reports a single indexed study location in Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00382668 about?
NCT00382668 is a clinical study titled "A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug". The primary purpose of this study is to evaluate how a person with liver impairment processes and reacts to the study drug. Information about any side effects that may occur will also be collected.
What is the current status of trial NCT00382668?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2006-10. Estimated completion is 2007-08.
What conditions does trial NCT00382668 study?
This clinical trial studies the following conditions: Liver Diseases.
What interventions are being tested in trial NCT00382668?
The interventions under investigation include: Dasatinib (DRUG).
Who is sponsoring clinical trial NCT00382668?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00382668 being conducted?
This trial has 4 study locations across Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00382668's enrollment target sits among peer trials
40 26th of 33 higher than 7 of 33 other Liver Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Veteran-Centered Care for Advanced Liver Disease (Vet-CALD)
RECRUITING · NA
-
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
RECRUITING · NA
-
MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
RECRUITING
-
The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial
RECRUITING · Phase 1
-
Genetic Collection Protocol
RECRUITING
-
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia